4.7 Article

Rapid Diagnostics and Appropriate Antibiotic Use

期刊

CLINICAL INFECTIOUS DISEASES
卷 52, 期 -, 页码 S357-S360

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir051

关键词

-

资金

  1. Food and Drug Administration
  2. Infectious Diseases Society of America
  3. AstraZeneca Pharmaceuticals
  4. Bio Merieux, Inc.
  5. Cepheid
  6. Gilead Sciences
  7. Intelligent MDX, Inc.
  8. Inverness Medical Innovations
  9. Roche Molecular Systems

向作者/读者索取更多资源

Most antibiotics are prescribed by physicians lacking postgraduate training in infectious diseases. As such, prescribing physicians have varying levels of interest and sophistication in thinking about how to use molecular and microbiological data to inform therapeutic choices. Strategies designed to modify physician antimicrobial-prescribing practices must therefore choose simplicity over complexity and must acknowledge our fundamental ignorance of many of the specifics of antibiotic-microorganism interactions. They must also acknowledge the critical nature of bacterial illnesses in hospitalized patients and the importance of delivering effective antimicrobial therapy early in the illness. Back-end strategies that evaluate therapy at defined intervals will be more readily accepted than strategies limiting physician choices early in the illness. It is therefore critical that we develop rapid and reliable microbiological assays, evidence-based recommendations on appropriate durations of therapy, and accurate surrogate markers of infection resolution.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据